Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: A cause for concern?

Journal of Bone and Joint Surgery - Series B

Volumn 93 B, Issue 10, 2011, Pages 1289-1295

  Yoon, R S ^a,b   Hwang, J S ^a   Beebe, K S ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

DRUG EFFICACY; DRUG MECHANISM; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, STRESS; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES;

EID: 80053525537     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.93B10.26924     Document Type: Review

References (69)

1. No authors listed. US Federal Drug Administration: approved drug products with therapeutic equivalence evaluations, 2011. http://www.accessdata.fda.gov/ scripts/cder/ob/docs/obdetail.cfm?Appl-No=020560&TABLE1=OB-Rx (date last accessed 28 June 2011).
2. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-2294.
3. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011;305:783-789.
4. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: fracture intervention trial research group. Lancet 1996;348:1535-1541. (Pubitemid 26411651)
5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-1822. (Pubitemid 46698462)
6. Chrischilles EA, Dasbach EJ, Rubenstein LM, et al. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int 2001;12:654-660. (Pubitemid 32889166)
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082. (Pubitemid 29014065)
8. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-289. (Pubitemid 34219441)
9. Eastell R, Lang T, Boonen S, et al. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporos Int 2010;21:1277-1285.
10. Quandt SA, Thompson DE, Schneider DL, Nevitt MC, Black DM. Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc 2005;80:343-349. (Pubitemid 40316296)
11. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-982.
12. Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009;361:818-820.
13. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761-1771.
14. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg [Am] 2009;91-A:2556-2561.
15. Ha YC, Cho MR, Park KH, Kim SY, Koo KH. Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy? Clin Orthop 2010;468:3393-3398.
16. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-231.
17. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-1306. (Pubitemid 351439247)
18. Sayed-Noor AS, Sjödén GO. Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop 2009;467:1921-1926.
19. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
20. Francis MD, Russell RG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969;165:1264-1266.
21. Russell RG, Bisaz S, Fleisch H. Pyrophosphate and diphosphonates in calcium metabolism and their possible role in renal failure. Arch Intern Med 1969;124:571-577.
22. Felix R, Graham R, Russell G, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976;429:429-438.
23. Fast DK, Felix R, Dowse C, Neuman WF, Fleisch H. The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 1978;172:97-107. (Pubitemid 8309691)
24. Felix R, Bettex JD, Fleisch H. Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells. Calcif Tissue Int 1981;33:549-552. (Pubitemid 12181111)
25. Felix R, Fleisch H. Increase in fatty acid oxidation in calvaria cells cultured with diphosphonates. Biochem J 1981;196:237-245. (Pubitemid 11079502)
26. Felix R, Fleisch H. The effect of diphosphonates on periosteal and bone cells in culture. Experientia 1981;37:817-819. (Pubitemid 11052314)
27. Reitsma PH, Teitelbaum SL, Bijvoet OL, Kahn AJ. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 1982;70:927-933. (Pubitemid 13254916)
28. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986;38:227-233. (Pubitemid 16137016)
29. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-2105.
30. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-290. (Pubitemid 26305769)
31. Schmidt A, Rutledge SJ, Endo N, et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A 1996;93:3068-3073. (Pubitemid 26114364)
32. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-138. (Pubitemid 29036065)
33. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001;296:235-242. (Pubitemid 32112446)
34. Suri S, Mönkkönen J, Taskinen M, et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001;29:336-343. (Pubitemid 32930060)
35. Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-4796. (Pubitemid 32055161)
36. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-241. (Pubitemid 30046509)
37. Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep 2003;5:65-74.
38. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004;4:711-719. (Pubitemid 39149473)
39. Frith JC, Mönkkönen J, Auriola S, Mönkkönen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-2210. (Pubitemid 33644066)
40. Lehenkari PP, Kellinsalmi M, Näpänkangas JP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002;61:1255-1262. (Pubitemid 34441791)
41. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443.
42. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997;157:2617-2624. (Pubitemid 27519982)
43. Hochberg MC, Thompson DE, Black DM, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20:971-976. (Pubitemid 40712821)
44. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial: FIT Research Group. J Clin Endocrinol Metab 2000;85:4118-4124. (Pubitemid 32055362)
45. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006;21:292-299. (Pubitemid 43265295)
46. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938. (Pubitemid 46021497)
47. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004;19:1259-1269. (Pubitemid 41094366)
48. Boonen S, Black DM, Colón-Emeric CS, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010;58:292-299.
49. Eastell R, Black DM, Boonen S, et al. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab 2009;94:3215-3225.
50. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-661. (Pubitemid 34815869)
51. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007;357:1799-1809. (Pubitemid 350044800)
52. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301. (Pubitemid 40463979)
53. Schneider JP. Should bisphosphonates be continued indefinitely?: an unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006;61:31-33. (Pubitemid 43134037)
54. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 2010;304:1480-1484.
55. Wernecke G, Namduri S, Dicarlo EF, Schneider R, Lane J. Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J 2008;4:123-127.
56. Das De S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg [Br] 2010;92-B:679-686.
57. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br] 2007;89-B:349-353. (Pubitemid 46563912)
58. Issacs JD, Shidiak L, Harris IA, Szomor ZL. Femoral insufficiency fractures associated with prolonged bisphosphonate therapy. Clin Orthop 2010;468:3384-3392.
59. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009;20:1353-1362.
60. Yoon RS, Beebe KS, Benevenia J. Prophylactic bilateral intramedullary femoral nails for bisphosphonate-associated signs of impending subtrochanteric hip fracture. Orthopedics 2010;33:267-270.
61. Somford MP, Draijer FW, Thomassen BJ, et al. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009;24:1736-1740.
62. Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol 2010;194:1581-1586.
63. Loizou CL, McNamara I, Ahmed K, Pryor GA, Parker MJ. Classification of subtrochanteric femoral fractures. Injury 2010;41:739-745.
64. No authors listed. FDA Drug Safety Communication: safety update for osteoporosis drugs, bisphosphonates, and atypical fractures, 2010. http://www.fda.gov/drugs/drugsafety/ucm229009.htm (date last accessed 27 June 2011).
65. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007;22:1502-1509. (Pubitemid 351229320)
66. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-1300. (Pubitemid 39120794)
67. Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a registerbased national cohort analysis. J Clin Endocrinol Metab 2010;95:5258-5265.
68. Wang Z, Bhattacharyya T. Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 2011;26:553-560.
69. Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-1737.